Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Prucalopride Tablets in the US market Post FDA Approval
Details : Motegrity-Generic (Prucalopride Succinate) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Product Name : Motegrity-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2025
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Nora Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Sunshine Biopharma to Launch Two GI Drugs in $200M Canadian Market
Details : Nora Pharma has acquired the rights to two gastrointestinal drugs, which includes Motegrity-Generic (prucalopride succinate). It is indicated for the treatment of chronic idiopathic constipation.
Product Name : Motegrity-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2025
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Nora Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces FDA Approval of Prucalopride with CGT Exclusivity
Details : Prucalopride is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Product Name : Motegrity
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2025
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Prucalopride For Functional Constipation in Children and Teenagers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2014
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Prucalopride Versus Placebo in Gastroparesis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2014
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Hotel Dieu Hospital | Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2013
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Hotel Dieu Hospital | Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2013
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2012
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2012
Lead Product(s) : Prucalopride Succinate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable